Apogee Therapeutics/$APGE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Ticker

$APGE
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Waltham, United States

Employees

196

ISIN

US03770N1019
Website
www.apogeetherapeutics.com

APGE Metrics

BasicAdvanced
$2.3B
-
-$3.59
-
-

Bulls say / Bears say

Analysts have set a consensus price target of $93.88 for Apogee Therapeutics, indicating a potential upside of approximately 134% from its current trading price. (nasdaq.com)
The company's lead candidate, APG777, has shown promising interim Phase 1 results for atopic dermatitis, with a notably long half-life that could reduce dosing frequency, potentially offering a competitive advantage over existing treatments. (seekingalpha.com)
Apogee Therapeutics has a robust pipeline targeting significant markets in inflammatory and immunology diseases, including atopic dermatitis, asthma, and COPD, positioning it well for future growth. (stocktitan.net)
Despite positive developments, Apogee Therapeutics reported a net loss of $1.19 per share in its latest earnings report, missing analysts' consensus estimates and raising concerns about its current profitability. (defenseworld.net)
The company's stock has experienced significant volatility, with a 52-week range between $26.20 and $63.50, which may indicate market uncertainty regarding its future performance. (uspostnews.com)
Apogee Therapeutics operates in a highly competitive biotech sector, facing challenges from established players with approved treatments, which could impact its market share and revenue growth. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

APGE News

AllArticlesVideos
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug

Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug

Proactive Investors·2 weeks ago
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

GlobeNewsWire·2 weeks ago
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $APGE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs